AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition

Xinyu Shao1*, Jue Wu2*, Shunying Yu1, Yuqing Zhou1, Chunli Zhou1

1Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China
2Department of Obstetrics and Gynecology, The Suzhou Dushu Lake Hospital, Suzhou Municipal Hospital, Suzhou, Jiangsu, China
*Equal contribution

Correspondence to: Chunli Zhou; email: zhouchunli@njmu.edu.cn, https://orcid.org/0000-0001-7369-4320
Keywords: AKR1B10, gastric cancer, proliferation, migration, EMT
Received: July 3, 2021 Accepted: September 7, 2021 Published: September 22, 2021

Copyright: © 2021 Shao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Gastric cancer (GC) is a common malignancy around the world with a poor prognosis. Aldo-keto reductase family 1 member B10 (AKR1B10) is indispensable to cancer development and progression, which has served as a diagnostic biomarker for tumors. In our study, we demonstrated that the expression of AKR1B10 in GC tissues was significantly lower compared with normal gastric tissues. Subgroup analysis showed that, according to the clinic-pathological factors, the effect of the AKR1B10 expression level on the prognosis of GC patients was significantly different. Moreover, reduced expression of AKR1B10 promoted the ability of GC cells in proliferation and migration. Furthermore, increased AKR1B10 levels resulted in the opposite trend in vitro. Moreover, AKR1B10 was correlated with epithelial-mesenchymal transition (EMT) in a significant way. In vivo experiment, knockdown of AKR1B10 promoted the growth of tumor, increased Vimentin, and E-cadherin significantly. In summary, AKR1B10 is considered as a tumor suppressor in GC and is a promising therapeutic target.

INTRODUCTION

Gastric cancer (GC) is one of the most common digestive malignancies around the world [1], especially in East Asia such as China. Due to continuous development in the diagnosis and treatment of GC, the incidence of GC is gradually decreasing, and in particular, the number of cases of early gastric cancer among all the cases of GC is rapidly on the rise. What we urgently need is to explore the development of GC and identify novel therapeutic targets. Aldo-keto reductase family 1 member B10 is a 36-kD cytosolic NADPH-dependent oxidoreductase [2]. AKR1B10 is mainly expressed in digestive tract tissues such as the stomach, small intestine, and colorectum. In the liver, thymus and prostate, the expression can be low, but in other normal tissues the expression is zero [2–5]. AKR1B1 and AKR1B10 have a similar structure but the functions are different [6, 7]. AKR1B1 participates in the conversion of glucose into sorbitol. Thus, this enzyme has been found to be involved in the pathophysiologival processes of diabetes. The effect of AKR1B10 on glucose is not known, but it has been proven to be involved in the metabolism of 4-hydroxynonenal, acrolein and phospholipid aldehydes [8, 9]. Increasingly researches have demonstrated that AKR1B10 is indispensable to development of GC, and targeted therapy for AKR1B10 may be an effective treatment regimen. As reported, AKR1B10 has been shown to be secreted via nonclassical pathway mediated by lysosome [10]. In addition, it is well known to be overexpressed in human pancreatic cancer, hepatocellular carcinoma, and lung cancer [2, 8, 11, 12]. However, most studies on the effects of AKR1B10 on tumors have focused on non-gastrointestinal tumors. The role of gastrointestinal tumors has not yet been elucidated.
The ability of GC cells in proliferation and metastasis are caused by abnormal activation of epithelial-mesenchymal transition (EMT), which is activated by factors such as TGF-β and EMT inducers, including Snail, while some inducers, such as α-SMA have opposite regulatory effects [13, 14]. Our findings demonstrated that EMT of GC cells was likely regulated by AKR1B10. Furthermore, alteration of AKR1B10 level affected characteristics of GC cells such as proliferation and migration.

Due to differential expression of AKR1B10 in gastrointestinal tumors and other tumors, the feasibility of targeted therapy for AKR1B10 is not clear [6, 8, 11, 15]. Few studies demonstrated the value of AKR1B10 in diagnosing, estimating prognosis as well as impacting the functional behavior of tumor. Additional studies on whether AKR1B10 can be a potential target for gastrointestinal cancer therapy are critical.

**MATERIALS AND METHODS**

**Human tissue specimens**

Human GC and adjacent normal tissues were collected immediately after radical surgical resection. Total 117 paired specimens were collected from 2010 to 2012. All samples were obtained with informed consent from patients who had not undergone radiotherapy or chemotherapy prior to surgery. All specimens were histo-pathologically verified. In accordance with the guidelines of Independent Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University (IRB approval number, KL901066) (Nanjing, China), the study was approved and all patients signed informed consent.

**Immunohistochemistry (IHC) evaluation**

10% formalin was used to fix the tumor tissues, after embedding, the tissues were continuously cut into 5-µm-thick slices. Sections were dewaxed, rehydrated, quenched with hydrogen peroxide in methanol, and blocked with 10% normal goat serum for 30 min. After blocking, per sample was incubated overnight with a 1:100 dilution polyclonal anti-human AKR1B10 (Abclonal, China) at 4°C or at room temperature for 2 hours. In accordance with manufacturer's protocol, processed tissues were immunostained using tissue staining kit (Zhongshan Biotechnology, China) and scored by two authors respectively [16].

**Bioinformatics analysis**

AKR1B10 expression and the effect it exerts on the prognosis were analyzed by the GEPIA (http://gepia.cancer-pku.cn) and Oncomine (http://www.oncomine.org) platform. The level of AKR1B10 in GC cell was searched from CCLE (https://portals.broadinstitute.org/ccle) platform. All the information obtained was analyzed by established protocols.

**Cell culture and transfection**

Cell Bank of Chinese Academy of Sciences (Shanghai, China) was the source of GC cell lines (MKN45 and AGS). At 37°C under 5% CO₂, MKN45 and AGS cells were cultured in RPMI 1640 medium (Hyclone, USA), supplemented with 10% fetal bovine serum (Gibco, USA). Specific ingredients include penicillin G sodium (100 U/ml) and streptomycin (100 µg/ml). The prepared human AKR1B10-shRNA was transfected into MKN45 cells. AGS cells were processed by AKR1B10 cDNA plasmid [17].

**Protein isolation and western blot analysis**

As manufacturer’s protocol, GC cells were lysed in ice-cold RIPA lysis buffer supplemented with protease and phosphatase inhibitors. Extracted proteins were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, USA).

After blocking with 5% non-fat milk for 1 h, membranes were incubated overnight with antibodies at 4°C. Protein bands were visualized by chemiluminescence and quantified by ImageJ for Windows (NIH, USA). Specific antibodies include: anti-AKR1B10 (1:1000; no. bs-6274R; Bioss), anti-E-cadherin (1:1000; no. bs-1016R; Bios), anti-vimentin (1:1000; no. bs-23063R; Bios) and anti-GAPDH (1:5000; no. bs-0755R; Bios).

**RNA isolation and quantitative real-time PCR (qRT-PCR)**

Total RNA of GC tissues or cells was extracted by TRIzol reagent (Invitrogen, Life Technologies, USA). After reverse transcription by a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA), as manufacturer’s instructions, qRT-PCR was conducted by Power SYBR® Green PCR Master Mix (ABI, USA) and 7500 real time PCR system (ABI, USA).

β-actin was used as the internal control. The primer sequences were as follows: AKR1B10 forward (5'-CCTTAATGATTAAAGTTGGAACAATGAT-3') and reverse (5'-GGAGAATGCAGCATTGATAG-3'); E-cadherin forward (5'-CAGAAGGCGTGCTGTAATG-3') and reverse (5'-GATTAATGGAATGGAATG-3'); Vimentin forward (5'-GAGAACGTTGGAACAG-3').
Animal experiments were performed in quality control (NC) groups, the levels of experimental cells were measured by means of Supplementary Figure 1E). By means of optical microscope (Nikon, Japan) that was equipped with digital camera (Nikon, Japan), we counted the number of colonies at 40× magnification.

**Cell migration assay**

Detection of cell migration via Transwell plates (Corning Incorporated, USA) and by means of a microscope at 200× magnification to observe [17]. Five fields were selected per specimen for quality statistics. The final result was calculated after removing one maximum and minimum value.

**Subcutaneous xenograft establishment**

Male BALB/c nude mice (3-5-week old, 16-18 g, specific pathogen-free grade) were obtained from Shanghai SLRC Laboratory Animal Co. Ltd. (Shanghai, China). Mice were randomly divided into AKR1B10 knock down (KD) and negative control (NC) groups (n = 5). 5 × 10⁶ AKR1B10-KD or NC-shRNA MKN45 were injected into left and right dorsal flank on day 0 subcutaneously [18]. Animal experiments were approved by the Animal Ethics Committee of the Affiliated Suzhou Hospital of Nanjing Medical University (Nanjing, China).

**Statistical analysis**

Different data were compared using chi-squared, Student's t-test (unpaired, two-tailed), Mann–Whitney U test or one-way ANOVA. All data were presented as the mean ± SD. Moreover, Kaplan-Meier curves were plotted for survival analysis. SPSS version 25.0 (IBM, USA), R programs (https://cran.r-project.org) and GraphPad Prism 8 (USA) were conducted to analyze statistics. P < 0.05 was considered statistically significant.

**RESULTS**

**AKR1B10 is upregulated in GC tissues and associated with clinico-pathological factors**

AKR1B10 expression levels were searched in multiple cancer types via the GEPIA Platform. Compared with para-tumor tissues, the levels of AKR1B10 in GC tissues were decreased in a significantly way (Supplementary Figure 1A–1B). Furthermore, in a certain of non-gastrointestinal tissues, the expression of AKR1B10 in most tumor tissues was higher in comparison to normal tissues (Supplementary Figure 1A). High levels of AKR1B10 may predict prolonged disease-free survival (DFS) in the TCGA dataset by GEPIA significantly (Supplementary Figure 1C), while an overall survival (OS) was not affected by AKR1B10 expression (Supplementary Figure 1D). The results of the Oncomine platform showed that, compared to non-tumor tissues, AKR1B10 mRNA levels in GC tissues were increased in Cui and DErrico datasets (Supplementary Figure 1E). For further analysis, 5 datasets of Oncomine platform were used to compare AKR1B10 mRNA expression in GC and normal tissues. The results revealed a similar expression trend (Supplementary Figure 1F).

To confirm the expression of AKR1B10 in GC, 117 specimens were analyzed for AKR1B10 expression (Figure 1A). Quantification of IHC scores indicated a significant reduction about AKR1B10 levels in GC compared with normal gastric tissues (Figure 1B, Supplementary Figure 2). In addition, AKR1B10 decreased in patients with lymph node metastasis in a significant way compared with patients without (Figure 1C). Furthermore, the expression of AKR1B10 was related to stage of tumor, that is, the expression level in tumor-node-metastasis (TNM) stage III–IV was lower than that in I–II (Figure 1D). Datasets from the GEPIA and Oncomine platforms further validate our results.

A summary about AKR1B10 and clinico-pathological characteristics was made in Table 1. The expression of AKR1B10 had significant association with tumor size (P < 0.001), depth of invasion (P < 0.001), lymph node metastasis (P < 0.001), venous invasion (P = 0.002), and TNM stage (P < 0.001), while no correlation with other clinico-pathological variables such as age, gender, degree of differentiation or neural invasion (P > 0.05). Additionally, AKR1B10 can be used as a single factor to predict univariate risk, determined by Cox's proportional hazard model analysis (Table 2).
Maintained level of AKR1B10 improved prognosis of GC patients

In accordance with IHC scores, patients who expressed AKR1B10 positive or negative were divided into different subgroups. Results indicated the fact that AKR1B10\textsuperscript{pos} patients suffered worse post-surgery overall survival than that of AKR1B10\textsuperscript{neg} patients (Figure 1E). Interestingly, in patients with TNM stages I–II, maintained AKR1B10 expression was associated with favorable in patients with TNM stages I–II but not stage III–IV patients ($P = 0.030; P = 0.942$; Figure 1F–1G).

For further elucidate the value of AKR1B10 in prognosis, patients were divided into different subgroups according to AKR1B10 expression levels (Figure 2). No matter how degree of infiltration depth, lymph node metastasis and differentiation vary, AKR1B10 expression exerted no obvious effect on the prognosis of GC patients. However, AKR1B10\textsuperscript{pos} patients with smaller tumor size ($P = 0.013$), negative venous invasion ($P = 0.001$), negative neural invasion ($P < 0.001$) and TNM stage I–II ($P = 0.035$) faced a worse prognosis. Conversely, for patients with tumor size larger than 5cm ($P = 0.283$), venous invasion ($P = 0.862$), neural invasion ($P = 0.694$), and TNM stage III–IV ($P = 0.944$), the impact of AKR1B10 on disease prognosis is insignificant.

Age, gender, tumor size, differentiation, vascular invasion, neural invasion, TNM stage, and AKR1B10 expression were applied to evaluate 3- and 5- year OS. The nomogram gave every prognostic variable a score on the point scale. We obtained scores associated with each prognostic variable and calculated the overall score (Figure 3).

**Increased AKR1B10 expression inhibits the ability of GC cells in proliferation and migration**

To further elucidate the link between AKR1B10 and GC cells, we determined the AKR1B10 expression level of GC cells by the CCLE platform (Figure 4A–4B).

Due to the fact that AKR1B10 expressed highly in MKN45 cells and low in AGS, MKN45 cells were transfected with control- or AKR1B10-shRNA to knockdown AKR1B10. AGS cells were transfected

---

**Figure 1. Expression of AKR1B10 in gastric cancer tissues.** (A) Representative immunohistochemistry images showing in situ AKR1B10 expression in gastric cancer (GC) and normal tissues (scale bar = 100 μm). (B–D) IHC scores of AKR1B10 in (B) GC vs normal tissues, (C) tumors with and without lymph node invasion, and (D) TNM stage I–II vs III–IV. (E–G) overall survival analysis of (E) AKR1B10\textsuperscript{pos} vs AKR1B10\textsuperscript{neg} GC patients, and in subgroups overall survival analysis of TNM stage I–II (F) and III–IV (G). LNM, Lymph node metastasis.
Table 1. Relationship between AKR1B10 and clinic-pathological factors in GC patients.

| Variables                        | AKR1B10 |   |   |   |
|----------------------------------|---------|---|---|---|
|                                  | Negative| Positive|   |   |
| Age (years)                      |         |         |   |   |
| ≤60                              | 25      | 19     | 0.606|
| >60                              | 45      | 28     |   |
| Gender                           |         |         |   |   |
| Male                             | 53      | 37     | 0.705|
| Female                           | 17      | 10     |   |
| Tumor size (cm)                  |         |         |   |   |
| <5                               | 38      | 41     | <0.001*|
| ≥5                               | 32      | 6      |   |
| Depth of tumor invasion          |         |         |   |   |
| T1–2                             | 10      | 21     | <0.001*|
| T3–4                             | 60      | 26     |   |
| Lymph node metastasis            |         |         |   |   |
| No                               | 18      | 31     | <0.001*|
| Yes                              | 52      | 16     |   |
| Degree of differentiation        |         |         |   |   |
| Well                             | 32      | 27     | 0.213|
| Poor                             | 38      | 20     |   |
| Venous invasion                  |         |         |   |   |
| Negative                         | 39      | 39     | 0.002*|
| Positive                         | 31      | 8      |   |
| Neural invasion                  |         |         |   |   |
| Negative                         | 43      | 35     | 0.142|
| Positive                         | 27      | 12     |   |
| TNM staging                      |         |         |   |   |
| I–II                             | 25      | 37     | <0.001*|
| III–IV                           | 45      | 10     |   |

*P < 0.05.

Table 2. Results of univariate and multivariate analyses of postoperative patients’ survival by Cox’s proportional hazard model.

| Varieties                              | n   | Univariate analysis |   |   | Multivariate analysis |   |   |
|----------------------------------------|-----|--------------------|---|---|------------------------|---|---|
|                                        |     | HR    | 95% CI      | p value | HR    | 95% CI      | p value |
| Age (≤60 or > 60 years)                | 44/73 | 0.796 | 0.503–1.259 | 0.330 | 0.795 | 0.464–1.361 | 0.402 |
| Gender (Male/Female)                   | 90/27 | 0.902 | 0.540–1.507 | 0.694 |          |   |   |
| Size of tumor (≤5 or > 5 cm)           | 79/38 | 0.356 | 0.226–0.560 | <0.001* |          |   |   |
| Depth of tumor invasion (T1–2/T3–4)   | 31/86 | 0.241 | 0.137–0.421 | <0.001* |          |   |   |
| Lymph node metastasis (negative/positive) | 49/68 | 0.271 | 0.168–0.437 | <0.001* |          |   |   |
| Degree of differentiation (moderate-well/poor) | 59/58 | 0.576 | 0.374–0.887 | 0.012* |          |   |   |
| Venous invasion (negative/positive)    | 78/39 | 0.384 | 0.247–0.597 | <0.001* |          |   |   |
| Neural invasion (negative/positive)    | 78/39 | 0.466 | 0.297–0.729 | <0.001* |          |   |   |
| TNM staging (I–II/III–IV)              | 62/55 | 0.243 | 0.153–0.385 | <0.001* |          |   |   |
| AKR1B10 expression (negative/positive) | 70/47 | 2.401 | 1.504–3.832 | <0.001* |          |   |   |

*P < 0.05.
with vector or AKR1B10 overexpression plasmid to amplify AKR1B10 (Figure 4C–4D). For further analyzed the biological characteristics of AKR1B10, we conducted knockdown (KD) and overexpression (OE) constructs. What we found is that AKR1B10-KD increased cellular proliferation ability, whereas that of AKR1B10-OE was reduced (Figure 4E–4F). Consistent with these findings, AKR1B10-KD cells strengthened colony-formation (Figure 4G–4H) and migration (Figure 4I–4J) ability, whereas AKR1B10-OE cells indicated reversed impacts.

**Expression of AKR1B10 is associated with the EMT in GC**

AKR1B10 regulated the ability of GC cells to proliferate and migrate negatively. However, EMT is closely related to migration of tumor cells. Therefore, what deserves further determination is whether AKR1B10 affect EMT of tumor or not. Correlation between AKR1B10 mRNA expression and EMT-related gene expression was analyzed in GC specimens from the TCGA dataset by the GEPIA platform. Specifically speaking, between AKR1B10 mRNA expression and EMT-related genes, including Vimentin (Figure 5A), Snail family transcriptional repressor 1, 2 (SNAI1, 2 Supplementary Figure 3A, 3B), zinc finger E-box binding homeobox 1, 2 (ZEB1, 2 Supplementary Figure 3C, 3D), signified a negative correlation, whereas correlated with E-cadherin positively (Figure 5B).

Next, we assessed AKR1B10, Vimentin, and E-cadherin mRNA levels in GC tissues. Compared with 19 paired normal gastric tissues, AKR1B10 expression was downregulated in GC tissues (Figure 5C, Supplementary Figure 4A–4B). Moreover, Vimentin was elevated and E-cadherin was reduced in GC tissues (Figure 5D–5E). According to the results of AKR1B10, Vimentin and E-cadherin mRNA level in 19 GC tissues, AKR1B10 indicated a negative correlation with Vimentin while correlated with E-cadherin positively (Figure 5F). Additionally, the detection of E-cadherin and Vimentin were conducted by immunoblot analysis (Figure 5G). AKR1B10 silencing significantly reduced the expression of E-cadherin and increased that of Vimentin. In contrast, AKR1B10 overexpression affected expression of EMT markers oppositely (Figure 5H). Taken together, it is not difficult to draw conclusion that AKR1B10 is crucial to EMT in GC cells.

**AKR1B10 inhibits gastric tumorigenesis in vivo**

For further analyze how AKR1B10 impacted GC cell growth, wild-type and AKR1B10-KD MKN45 cells

![Table](https://via.placeholder.com/150)

*Figure 2. Subgroup analysis of the influence of AKR1B10 expression on the survival of gastric cancer patients.*
were used as an *in vivo* xenograft model. Depletion of AKR1B10 exerted the reduction of body weight in mice (Figure 6A), and facilitated GC cells proliferation, which was manifested by the fact that tumor size (Figure 6B–6C) and weight (Figure 6D) were greater than that of NC group. The difference in body weight between AKR1B10-KD and control group without tumors was obvious (Figure 6E). Additionally, *in situ* mRNA levels of AKR1B10 and E-cadherin indicated a reduction in a significant way, whereas Vimentin was higher in AKR1B10-KD group (Figure 6F–6H). Results showed a significant correlation (Figure 6J).

DISCUSSION

The AKR1B subgroup is associated with numerous diseases, such as diabetes and cancers. AKR1B10 is one of the subgroups included in AKR1B [2]. The expression of AKR1B10 is primarily distributed in

![Figure 3. Nomograms to predict survival of gastric cancer patients.](image)

Points of each variable were obtained via a vertical line between each variable and the point scale. The predicted survival rate was correlated with the total points by drawing a vertical line from the total points scale to the overall survival.
digestive tract, meaning that the expression in non-digestive tract tissues is low. Moreover, what calls for special attention is that the level of AKR1B10 is opposite in tumors. It was found that AKR1B10 has enzymatic activity for substrates including retinaldehyde [19] and lipid peroxidation products [20].

AKR1B10 is indispensable to the development of tumors, becoming a diagnostic biomarker for some tumors. Inhibiting AKR1B10 may be an ideal treatment strategy [21, 22]. An AKR1B10 inhibitor used widely in tumor treatment has recently attracted increased attention [23–25]. AKR1B10 had statistical difference in gastrointestinal and non-gastrointestinal tissues. However, the differences were reversed in tumor tissues. These findings attracted the attention of researchers and resulted in a differential effect of the targeted inhibition of AKR1B10 on tumor cells [9, 26, 27].

Figure 4. Effect of AKR1B10 on the cell proliferation and migration ability of gastric cancer cells. (A) AKR1B10 expression in gastric cancer (GC) cell lines from the CCLE platform. (B) Relative expression of AKR1B10 in GC cell lines according to RNAseq results via the CCLE platform. (C–D) Immunoblot showing AKR1B10 protein levels in MKN45 cells transfected with AKR1B10-shRNA (C) and in AGS cells transfected with the AKR1B10 overexpression plasmid (D), and gray value analysis via ImageJ. (E–J) Proliferation rates (E–F), colony forming ability (G–H), and migration ability (I–J) of AKR1B10-KD and AKR1B10-OE GC cells. CCLE, Cancer Cell Line Encyclopedia. NC, negative control. KD, knockdown. AKR1B10-shRNA. VEC, vector. OE, overexpression, AKR1B10 overexpression plasmid. Data are presented as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.
The level of AKR1B10 in GC tissues was significantly lower compared with that in normal tissues, demonstrated by TCGA database analysis via the GEPIA platform and tissue detection. At the same time, we demonstrated that the expression of AKR1B10 in TNM stage III–IV patients or patients with lymph node metastasis was lower than that in control group in a significant way. In the subgroup analysis, the predicting value of AKR1B10 in prognosis of GC was significantly different. This indicated that target therapy may be dependent on the subgroup conditions, which may appropriately reduce the effective population and improve the therapeutic effect [18].

For a novel target that is conductive to prevent and treat cancer, increasingly attention has been paid on inhibitors of AKR1B10 [25, 28, 29]. The analysis of these inhibitors improves the understanding of the important features to be considered in the design of these compounds: the inhibitors must properly match the binding sites of AKR1B10 [8]. In the treatment of non-gastrointestinal tumors, targeted therapy of AKR1B10 has an excellent effect. AKR1B10 may promote cell proliferation and inhibit cell apoptosis by regulating oncogene expression. By contrast, the downregulation of AKR1B10 in tumor cells suppresses the growth and progression of tumor [4, 11]. Studies have shown that the down-regulation of AKR1B10 promotes apoptosis, mediated by mitochondrial dysfunction and oxidative stress [30–32]. In addition, targeting against AKR1B10 and inducing autophagy of

Figure 5. Correlation between AKR1B10 and epithelial-mesenchymal transition. (A) Correlation analysis of AKR1B10 and Vimentin gene expression levels in gastric cancer (GC) patients by the GEPIA platform. (B) Correlation analysis of AKR1B10 and E-cadherin gene expression levels in GC patients by the GEPIA platform. (C–E) Comparison of AKR1B10 (C), Vimentin (D) and E-cadherin (E) mRNA levels in 19 paired GC and normal tissues. (F) Correlation between AKR1B10 and Vimentin, and between AKR1B10 and E-cadherin mRNA levels in GC tissues. (G) MKN45 cells transfected with NC or KD and (H) AGS transfected with VEC or AKR1B10-OE. The bands were semi-quantified by ImageJ and the results are presented as the mean ± SD. VIM, Vimentin; ECAD, E-cadherin; TPM, transcripts per million. NC, negative control; KD, knockdown; VEC, vector; OE, overexpression. **P < 0.01, ***P < 0.001.
tumor cells may effectively inhibit the growth of tumor cells. AKR1B10P1 is the pseudogene of oncogene AKR1B10 in hepatocellular carcinoma, noticed as being anomalous transcriptionally preliminarily. AKR1B10P1 stably impacts SOX4, EMT by sponging miR-138 directly, which modulates the regulating gene of SOX4 post-transcriptionally. Moreover, the phosphorylation of p70S6K at T389 was found a consistent reduction, which is known as a direct target of mTOR. In addition to phosphorylation of several proteins involved in protein synthesis, p70S6K can also affect the phosphorylation of proteins about cell growth, proliferation and motility. It also participates in the process of EMT. Whether AKR1B10 plays a specific function in GC associated with the EMT process is poorly understood [33, 34]. In this paper, we explored whether inhibition of AKR1B10 could affect proliferation and migration of GC cells, which may depend on the EMT process.

However, target treatment of AKR1B10 in gastrointestinal tumors has not been thoroughly studied, and the effect of AKR1B10 in gastrointestinal tumors has not been fully elucidated. Our study showed that in GC, inhibition of the expression level of AKR1B10 modestly promoted the capacity of tumor to proliferate, migrate and form colony. Furthermore, increased AKR1B10 expression can significantly inhibit the ability of GC cells in proliferation, migration, and colony formation. Therefore, we have the reason to believe that AKR1B10 impacts the proliferative and migratory ability of cells in gastrointestinal and non-gastrointestinal tumors reversely. In summary, the role of AKR1B10 in GC have not yet been fully elucidated. In addition, a accurate validation about the impact of

Figure 6. AKR1B10 knockdown promotes gastric cancer tumor growth in vivo. (A–B) Total body weight (A) and tumor volume (B) of the mice. (C) Representative pictures of subcutaneous tumors harvested from NC and AKR1B10-KD group. (D) The weights of tumor masses. (E) The weights of mice without tumor masses. (F–I) Relative AKR1B10 (F), Vimentin (G) and E-cadherin (H) mRNA levels in tumors of the AKR1B10-KD or NC group, and their correlation (I). (J) Stratification of mice into cluster 1 and cluster 2 according to AKR1B10 mRNA levels, body weight and tumor weight. (K) Percentage of NC and AKR1B10-KD mice in each cluster. Data are presented as the mean ± SD. NC, negative control; KD, AKR1B10 knockdown. * P < 0.05, ** P < 0.01.
AKR1B10 on growth of GC cells and tumor metastasis is still lacking. For the structure and function of AKR1B10, as well as AKR1B10 inhibitor interactions in GC deserve a comprehensive understanding, which may promote novel therapeutic strategies for GC especially combined with further studies.

**AUTHOR CONTRIBUTIONS**

C.Z. and X.S. designed the study. X.S., J.W., S.Y. and Y.Z. carried out experiments and analyses. C.Z. and X.S. revised the manuscript.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the valuable cooperation of Diyu Zhou (The First Affiliated Hospital of Soochow University) and Yizhou Yao (The First Affiliated Hospital of Soochow University) in assessing the IHC score and experimental technical guidance.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest related to this study.

**FUNDING**

This work was supported by the Suzhou Special Project of Diagnosis and Treatment for key Clinical Disease (LCZX201814), Suzhou Science and Technology Development Project (SYSD2018144) and Suzhou Integrated Traditional Chinese and Western Medicine Scientific Research Fund Project (SYSD2018208).

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. [https://doi.org/10.3322/caac.21492](https://doi.org/10.3322/caac.21492) PMID:30207593

2. Penning TM. The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2015; 234:236–46. [https://doi.org/10.1016/j.cbi.2014.09.024](https://doi.org/10.1016/j.cbi.2014.09.024) PMID:25304492

3. Sonohara F, Inokawa Y, Hishida M, Kanda M, Nishikawa Y, Yamada S, Fujii T, Sugimoto H, Kodera Y, Nomoto S. Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncol Lett. 2016; 12:4821–28. [https://doi.org/10.3892/ol.2016.5240](https://doi.org/10.3892/ol.2016.5240) PMID:28105190

4. Cheng BY, Lau EY, Leung HW, Leung CO, Ho NP, Gurung S, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer Res. 2018; 78:2332–42. [https://doi.org/10.1158/0008-5472.CAN-17-2445](https://doi.org/10.1158/0008-5472.CAN-17-2445) PMID:29483095

5. Fang CY, Lin YH, Chen CL. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients. J Oral Pathol Med. 2019; 48:712–19. [https://doi.org/10.1111/jop.12891](https://doi.org/10.1111/jop.12891) PMID:31237374

6. Taskoparan B, Seza EG, Demirkol S, Tuncer S, Stefek M, Gure AO, Banerjee S. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell Oncol (Dordr). 2017; 40:563–78. [https://doi.org/10.1007/s13402-017-0351-7](https://doi.org/10.1007/s13402-017-0351-7) PMID:28929377

7. Reddy KA, Kumar PU, Srinivasulu M, Triveni B, Sharada K, Ismail A, Reddy GB. Overexpression and enhanced specific activity of aldo-keto reductases (AKR1B1 & AKR1B10) in human breast cancers. Breast. 2017; 31:137–43. [https://doi.org/10.1016/j.breast.2016.11.003](https://doi.org/10.1016/j.breast.2016.11.003) PMID:27855345

8. DiStefano JK, Davis B. Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11:486. [https://doi.org/10.3390/cancers11040486](https://doi.org/10.3390/cancers11040486) PMID:30959792

9. Nishinaka T. [Aldo-keto reductase, AKR1B10]. Nihon Yakurigaku Zasshi. 2012; 139:275–76. PMID:22997641

10. Luo D, Bu Y, Ma J, Rajput S, He Y, Cai G, Liao DF, Cao D. Heat shock protein 90-α mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes. J Biol Chem. 2013; 288:36733–40. [https://doi.org/10.1074/jbc.M113.514877](https://doi.org/10.1074/jbc.M113.514877) PMID:24217247

11. Liu W, Song J, Du X, Zhou Y, Li Y, Li R, Lyu L, He Y, Hao J, Ben J, Wang W, Shi H, Wang Q. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model. Acta Biomater. 2019; 91:195–208. [https://doi.org/10.1016/j.actbio.2019.04.053](https://doi.org/10.1016/j.actbio.2019.04.053) PMID:31034948

12. Zhu R, Xiao J, Luo D, Dong M, Sun T, Jin J. Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study. Gastroenterol Hepatol. 2019; 42:614–21.
13. Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016; 21:965. https://doi.org/10.3390/molecules21070965 PMID: 27455225

14. Ramesh V, Brabletz T, Ceppi P. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors. Trends Cancer. 2020; 6:942–950. https://doi.org/10.1016/j.trecan.2020.06.005 PMID: 32680650

15. Yao Y, Wang X, Zhou D, Li H, Qian H, Zhang J, Jiang L, Wang B, Lin Q, Zhu X. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY). 2020; 12:13059–75. https://doi.org/10.18632/aging.103393 PMID: 32615540

16. Shao X, Cheng Z, Xu M, Mao J, Wang J, Zhou C. Prognosis, Significance and Positive Correlation of Rab1A and p-56k/Gli1 Expression in Gastric Cancer. Anticancer Agents Med Chem. 2019; 19:1359–67. https://doi.org/10.2174/1871520619666190416110851 PMID: 31038077

17. Yao Y, Zhou D, Shi D, Zhang H, Zhan S, Shao X, Sun K, Sun L, Wu G, Tian K, Zhu X, He S. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Biomed Pharmacother. 2019; 111:993–1004. https://doi.org/10.1016/j.biopha.2019.01.018 PMID: 30841479

18. Yao Y, Yang X, Sun L, Sun S, Huang X, Zhou D, Li T, Zhang W, Abumrad NA, Zhu X, He S, Su X. Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer. EBioMedicine. 2019; 41:256–67. https://doi.org/10.1016/j.ebiom.2019.01.066 PMID: 30738828

19. Gallego O, Belyaeva OV, Porté S, Ruiz FX, Stetserenko AV, Shabrova EV, Kostereva NV, Farrés J, Parés X, Kedishvili NY. Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J. 2006; 399:101–09. https://doi.org/10.1042/BJ20051988 PMID: 16787387

20. Shen Y, Zhong L, Johnson S, Cao D. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem Biol Interact. 2011; 191:192–98. https://doi.org/10.1016/j.cbi.2011.02.004 PMID: 21329684

21. Seliger JM, Cicek SS, Witt LT, Martin HJ, Maser E, Hintzepeter J. Selective Inhibition of Human AKR1B10 by n-Humulone, Adhumulone and Cohumulone Isolated from Humulus lupulus Extract. Molecules. 2018; 23:3041. https://doi.org/10.3390/molecules23113041 PMID: 30469331

22. Nie Q, Zhang X. Transcriptional profiling analysis predicts potential biomarkers for glaucoma: HGF, AKR1B10 and AKR1C3. Exp Ther Med. 2018; 16:5103–11. https://doi.org/10.3892/etm.2018.6875 PMID: 30542465

23. Ruiz FX, Cousido-Siah A, Porté S, Domínguez M, Crespo I, Rechlin C, Mitschler A, de Lera ÁR, Martín MJ, de la Fuente Já, Klebe G, Parés X, Farrés J, Podjarny A. Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10. ChemMedChem. 2015; 10:1989–2003. https://doi.org/10.1002/cmdc.201500393 PMID: 26549844

24. Cousido-Siah A, Ruiz FX, Crespo I, Porté S, Mitschler A, Parés X, Podjarny A, Farrés J. Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chem Biol Interact. 2015; 234:290–96. https://doi.org/10.1016/j.cbi.2014.12.018 PMID: 25532697

25. Zhang W, Wang L, Zhang L, Chen W, Chen X, Xie M, Yan G, Hu X, Xu J, Zhang J. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10. Steroids. 2014; 86:39–44. https://doi.org/10.1016/j.steroids.2014.04.010 PMID: 24793566

26. Banerjee S. (2021) Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks. In: Advances in Experimental Medicine and Biology. Springer, Cham. https://doi.org/10.1007/5584_2021_634

27. Endo S, Matsunaga T, Nishimaka T. The Role of AKR1B10 in Physiology and Pathophysiology. Metabolites. 2021; 11:332. https://doi.org/10.3390/metabo11060332 PMID: 34063865

28. Cousido-Siah A, Ruiz FX, Fanfrlík J, Giménez-Dejoz J, Mitschler A, Kamlar M, Veselý J, Ajani H, Parés X, Farrés J, Hobza P, Podjarny AD. IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors. ACS Chem Biol. 2016; 11:2693–705.
29. Chen W, Chen X, Zhou S, Zhang H, Wang L, Xu J, Hu X, Yin W, Yan G, Zhang J. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking. Steroids. 2016;110:1–8. https://doi.org/10.1016/j.steroids.2016.03.004 PMID:26968129

30. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem. 2009;284:26742–48. https://doi.org/10.1074/jbc.M109.022897 PMID:19643728

31. Zhou Z, Zhao Y, Gu L, Niu X, Lu S. Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. Mol Med Rep. 2018;17:2153–60. https://doi.org/10.3892/mmr.2017.8173 PMID:29207124

32. van Weverwijk A, Koundouros N, Iravani M, Ashenden M, Gao Q, Poullogiannis G, Jungwirth U, Isacke CM. Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 2019;10:2698. https://doi.org/10.1038/s41467-019-10592-4 PMID:31221959

33. Hao F, Fei X, Ren X, Xi Xiao J, Chen Y, Wang J. Pseudogene AKR1B10P1 enhances tumorigenicity and regulates epithelial-mesenchymal transition in hepatocellular carcinoma via stabilizing SOX4. J Cell Mol Med. 2020;24:11779–90. https://doi.org/10.1111/jcmm.15790 PMID:32924268

34. Demirkol Canlı S, Seza EG, Sheraj I, Gömüçeli I, Turhan N, Carberry S, Prehn JHM, Güre AO, Banerjee S. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway. Carcinogenesis. 2020;41:1219–28. https://doi.org/10.1093/carcin/bgaa072 PMID:32628753
SUPPLEMENTARY MATERIALS

Supplementary Figures

Supplementary Figure 1. Expression of AKR1B10 in gastric cancer in datasets. (A–B) Comparison of AKR1B10 levels in (A) multiple cancers, and (B) between gastric cancer (GC) and paired normal tissues in TCGA datasets via GEPIA platform. (C–D) disease free survival (C) and overall survival (D) were analyzed according to AKR1B10 expression level in GC tissues in the TCGA datasets via the GEPIA platform. (E) AKR1B10 mRNA levels in GC and non-tumor tissues in the datasets presented by the Oncomine platform. (F) Comparison of AKR1B10 mRNA expression in GC and normal tissues across 5 datasets by Oncomine platform.
Supplementary Figure 2. Immunohistochemistry images showing *in situ* AKR1B10 expression in gastric cancer tissues. Negative (A), weak (B), positive (C), strong positive (D). Scale bar = 100 μm.
Supplementary Figure 3. AKR1B10 is associated with epithelial-mesenchymal transition. (A) Correlation analysis between AKR1B10 and SNAI1 gene expression in patients with gastric cancer (GC) by GEPIA datasets. (B) Correlation analysis between AKR1B10 and SNAI2 gene expression in patients with GC by GEPIA datasets. (C) Correlation analysis between AKR1B10 and ZEB1 gene expression in patients with GC by GEPIA datasets. (D) Correlation analysis between AKR1B10 and ZEB2 gene expression in patients with GC by GEPIA datasets. SNAI1/2, Snail family transcriptional repressor 1/2; ZEB1/2, zinc finger E-box binding homeobox 1/2; TPM, transcripts per million.
Supplementary Figure 4. mRNA level of AKR1B10, E-cadherin and Vimentin expression in gastric cancer (GC) and paired normal tissues. (A–B) AKR1B10 mRNA levels in 19 paired GC and normal tissues (A), comparison of AKR1B10 expression in paired GC and normal tissues (B). (C–D) Vimentin mRNA levels in 19 paired GC and normal tissues (C), comparison of Vimentin expression in paired GC and normal tissues (D). (E–F) E-cadherin mRNA levels in 19 paired GC and normal tissues (E), and comparison of E-cadherin expression in paired GC and normal tissues (F).